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Stem Cell Transplantation
Reduced intensity conditioning allogeneic transplant for
advanced chronic lymphocytic leukemia
We report the preliminary results of 12 patients with
advanced stage chronic lymphocytic leukemia (CLL)
transplanted following reduced intensity conditioning
(RIC. With a median of 22 months of follow-up, 9
patients are alive and 3 have died of progressive disease,
graft-versus-host disease (GVHD) or toxic hepatitis.
Acute grade I-III GVHD occurred in 33% of patients and
chronic GVHD in 50%. Eight of the 12 patients achieved
a complete remission (CR) and 2 patients a partial remis-
sion (PR). Donor lymphocyte infusion was effective in 6
patients. Event-free survival, progression-free survival
and non-relapse mortality at 3 years were 68%, 42%
and 16%, respectively. Our results show successful
immunomodulation and reduction in tumor burden in
high risk CLL.haematologica 2004; 89:885-886
(http://www.haematologica.org/2004/7/885)
In recent years, a number of prognostic factors have been
found in patients with chronic lymphocytic leukemia (CLL).
Some of these factors identify patients with a poor-risk who
are resistant to conventional treatments and have a shorter
overall survival.1,2 An allogeneic transplant, supported by
clear evidence of a graft-versus-leukemia (GVL) effect, has
been restrained by treatment-related mortality of up to
50%.3,4 In recent years reduced-intensity conditioning regi-
mens (RIC) have replaced myeloablative regimens for some
elderly patients with CLL. After the first report by Khouri in
1998,5 several RIC regimens have been developed and proven
effective in lymphoproliferative disorders including CLL.6-8 We
now report on 12 patients with advanced-stage CLL trans-
planted with grafts from sibling HLA identical donors and
conditioned with two cycles of fludarabine 30 mg/m2/day for
3 days and cyclophosphamide 300 mg/m2/day for 3 days fol-
lowed by 200cGy total body irradiation (TBI) 14 days after
the second cycle. Graft-versus- host disease (GVHD) prophy-
laxis included cyclosporine-A and mycophenolate mofetil.
Patients were infused with growth factor-mobilized donor
peripheral blood stem cells (>5×106 CD34+ cells). 
Donor-recipient chimerism was assessed by micro-
chimerism9 on sorted peripheral blood CD3+ T cells (Mini-
MACS, Miltenyi Biotec, Germany). Analysis of minimal resid-
ual disease (MRD) and the expression of co-stimulatory mol-
ecules was performed by flow cytometry (FACSCalibur,
Becton Dickinson). Samples with fewer than 1×10-4
CD23/CD5/CD19 cells with a κ/λ ratio not shifted to more
than 2:1 were considered negative for MRD, in agreement
with the initial phenotype.10
The patients’ main characteristics and the outcome of the
transplant are summarized in Table 1. Myeloid and platelet
engraftment was always rapid and complete donor
chimerism was seen in 10/12 patients. Treatment-related
toxicity was very mild. Five patients showed a cytome-
galovirus (CMV) reactivation but only 1 developed CMV
infection of the upper gastrointestinal tract (day +40).
Following the reactivation of a pulmonary aspergillosis,
treated with voriconazole, one patient in CR died of toxic
hepatitis 20 months after the transplant. The overall inci-
Table 1. Main patients characteristics and the outcome of the transplant.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
1 M 59 B 3 72 multiple PB 100 107 56 60 0 0 never yes 4 mo PD 19 Richter 
rearrang. trans.
2 F 48 B 3 86 46xx PB 0 0 no 15 0 mild 15 yes 38 mos PR 45+
(mosDLI) (DLI)
3 F 56 B 3 132 trisomy 12 PB 0 15 23 210 0 mild never no 28 CR 38+
4 M 57 C 1 18 trisomy 12 PB 0 16 60 14 I 0 10 yes 11mo CR 20 toxic
(DLI) hepatitis
5 M 55 B 2 80 n.a. PB 1 0 40 20 II ext 15 no 30 CR 16 infection
6 M 45 B 1 161 11q- PB 0 0 33 28 III mild never no 30 CR 27+
7 M 52 C 2 112 n.a. BM 10 20 no 60 0 0 11 yes 60 CR/PD 29+
8 M 52 B 3 141 -3, -17 PB 0 141 19 mo 60 0 ext 26 yes 7mo CR 26+
(DLI)
9 M 51 B 1 101 46XY PB 0 13 no 28 0 mild never no 28 CR 22+
10 M 55 C 3 140 n.a. PB 12 120 no mix II 0 17 no 30 PR 22+
11 M 58 C 2 45 46XY PB 0 13 no mix 0 0 5 yes 50 PR 15+
12 M 55 C 2 24 13q- PB 0 0 no 6 mos 0 0 never no 30 CR 9+
1: patients; 2: sex; 3: age; 4: Stage (Binet); 5: lines of therapy; 6: months form diagnosis; 7: cytogenetics; 8: SC source; 9: PMN>1×109/L (days); 10: PLT>50×109/L (days);
11: CMV react: (days); 12: chimerism (day of FDC); 13: acute GVHD; 14: chronic GVHD; 15: CsA tapering (months); 16: DLI; 17: max response (days); 18: current status;
19: follow-up months; 20: cause of death.     
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dence of acute GVHD  grades I-III was 33%. One patient
developed acute grade II cutaneous GVHD on day +23, which
evolved into chronic sclerodermal-like GVHD, and died of
hypovolemic septic shock 20 months after the transplant.
One patient developed grade III hepatic GVHD on day +100,
which responded completely to prednisone and antithymo-
cyte globulin. Chronic GVHD involving either skin and
mucosa or liver was present in 6 patients (50%) (4 mild and
2 extensive) (1 after DLI infusion), but five patients are still
on cyclosporine treatment. Eight patients (66%) are in CR, as
evaluated by flow cytometry, after a median follow-up of 22
months (range 9-45). Clearance of CD23/CD5/CD19 below
the threshold of 1×104 peripheral blood cells was reached in
5 patients at a median time of 29 days after transplantation
(range 28-30). Three patients reached CR later, in two cases
after DLI. Two patients are in a good PR and one patient had
stable disease controlled by DLI infusions although Richter’s
transformation occurred 19 months after the transplant.
Overall, six out 12 patients (50%) were treated with DLI.
After a median observation period of 22 months (range 9-45)
9 patients are alive (75%) and 3 patients have died (25%).
The 3-year survival probability was estimated as 68%, while
progression-free survival was estimated as 42%. There were
no transplant-related deaths at day 100+ and 1 year. At 22
months probability of transplant related and relapse mortal-
ity were 16% and 8% respectively.
These data are comparable to those reported for other
series of CLL patients treated with reduced-intensity allo-
grafts.7,8 The incidence of both acute and chronic GVHD (33%
and 50%, respectively) was comparable to that described in
the EBMT study7 and lower than that reported by Schetelig
et al.,8 both including some form of T-cell depletion. In addi-
tion, we, in contrast to other authors,8 found that donor lym-
phocyte infusions were highly effective in half of the cases.
Since immune functions are known to be defective in CLL,
lymphocyte phenotypic analyses were performed before and
a mean time of 18 months after-transplant in order to detect
the host-immune reconstitution. As shown in Figure 1, after
interleukin-2 stimulation the percentage of cells expressing
the co-stimulatory molecules CD28 and CD154 (CD40 lig-
and) on T cells increased in 5 patients in complete
immunophenotypic remission.
These data suggest that RIC transplantation for advanced
stage CLL can achieve successful immunomodulation, a
reduction in tumor burden and, possibly, long-lasting com-
plete remission.
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Figure 1. Representative FACS analysis showing the
expression of co-stimulatory molecules (CD28 and
CD154) on gated CD3+ cells with and without 100 U/mL
interleukin-2 for 1 week in a) normal control b) pre-trans-
plant and c) post-transplant in immunophenotypic com-
plete remission. The upper right of each histogram indi-
cates the% of CD3+ expressing co-stimulatory molecules
(±SD of 8 and 5 samples). Open histograms show nega-
tive controls.
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